RMM RFP Guidance for Applicants

	Discovery	Translation	Clinical Trial	Infrastructure
Funding Amount*	Max of $200K	Max of $400K	Max of $500K - larger budgets may be allowable with adequate justification	Max of $200K
Funding Period	Up to 2 years	Up to 2 years	Up to 4 years	Up to 2 years
Objective	Supports exploratory research and discovery of novel regenerative medicine therapeutic approaches or innovations	Supports completion of activities necessary for advancement of regenerative medicine-based innovations towards clinical study or broad end use	Supports completion of activities through any stage clinical trial for regenerative medicine-based interventions	Supports Minnesota organization's capabilities to develop commercializable regenerative medicine-based innovations
Eligibility	Minnesota-based academic institutions and small-businesses performing scientific and/or medical research in the state of Minnesota are eligible for this opportunity. Small businesses (the "Entity") must be based, owned (≥50%), and operating in the state of Minnesota. For this definition, a small business must have at least 2 and no more than 100 affiliated full- or part-time employees. Entities must be registered with the state of Minnesota's Secretary of State Office (http://www.sos.state.mn.us/business-liens) prior to the application being submitted. The project Principal Investigator (PI) must be an employee of the applicant organization and authorized by the applicant organization to conduct the research and assume the responsibilities of the PI.			
Funded Activities	● Basic research into stem cell mechanisms or genetics ● Investigating stem cells as tools for drug discovery, development and disease modelling or or enabling regenerative medicine research and innovation ● Research tools related to DEI ● Modeling of cells/tissues (omics) ● Auxiliary research (biomarker discovery, gene editing, imaging tools)	● Activities that will lead to selection and/or translation of a novel candidate therapeutic, diagnostic, medical device, or tool for use in developing new drugs, devices, or disease models ● Feasibility and Proof of concept studies ● Developing a Target Product Profile ● IND and IDE-enabling studies ● Preparation for and conduct of regulatory meetings	● All activities necessary for the planning, conduct, and completion of a clinical trial ● Product development and manufacturing for the proposed clinical trial ● Correlative studies or comparability studies associated with a clinical trial ● Activities intended to promote and uphold principles of DEI in the conduct of the study	● Development of infrastructure to design, develop, manufacture, test, gain regulatory approval, and market regenerative products ● Purchase of non-expendable equipment or instrumentation to improve infrastructure for the development of regenerative medicine products ● Implementing Quality Management System & GMP standards
Review Criteria**	● Does the project hold the necessary significance and potential for impact? ● Is the rationale sound? ● Is the project well planned and designed? ● Is the project feasible?			

*Includes both direct and indirect costs
**Specific review criteria will be tailored to each RFP based on project type and expected outcomes.